ATON 009Alternative Names: ATON-009
Latest Information Update: 16 Jul 2016
At a glance
- Originator Aton Pharma
- Class Antidotes
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Poisoning
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Poisoning in USA
- 27 Jan 2011 Phase-I clinical trials in Poisoning in USA (unspecified route)
- 31 May 2010 Preclinical trials in Poisoning in USA (unspecified route)